Palatin is a New Jersey biopharmaceutical company developing peptide and small molecule medicines that target melanocortin receptors. PTN reports earnings on Mon, Nov 16, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | HC Wainwright & Co. | Reiterated | Buy |
Seasonality
How PTN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in PTN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PTN is in one of them and how their past PTN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PTN in an article yet. Here's the latest on the wider market.
About Palatin Technologies
Palatin is a biopharmaceutical company based in Cranbury, New Jersey. It develops drug candidates that act on the melanocortin receptor system, a group of receptors involved in inflammation, immune response, appetite and metabolism. Its main focus is treatments for obesity and rare diseases tied to this pathway, with other candidates aimed at eye, gut and immune conditions. The company generally works with pharmaceutical partners to license and commercialize its products.
- Headquarters
- Cranbury, NJ